Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-01 autologous chondrocyte therapy for knee osteoarthritis
jRCT2053220084Completed
- Sponsor
- Hirosaki Lifescience Innovation, Inc.
- Start
- Sep 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of CaReS in knee osteoarthritis (OA) (2 arms), sponsored by Hirosaki Lifescience Innovation, Inc. Primary endpoint: Change from baseline in WOMAC total score at 52 weeks. Started Sep 2022; status: completed.
02
Drugs
CaReS
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2053220084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053220084.